Targeted Drugs for Multiple Myeloma market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Targeted Drugs for Multiple Myeloma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Targeted Drugs for Multiple Myeloma market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Other
Segment by Application
Hospital
Drug Center
Clinic
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron